Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6706 to 6720 of 8904 results

  1. Surgical vessel sealing systems (MT798)

    In development Reference number: GID-MT594 Expected publication date: TBC

    Medical technologies guidance
    In development

  2. SILK artery reconstruction device (discontinued)

    Discontinued Reference number: GID-MT81

    Medical technologies guidance
    Discontinued

  3. Personal, social, health and economic education focusing on sex and relationships and alcohol education

    Discontinued Reference number: GID-PHG0

    NICE guideline
    Discontinued

  4. Maternal health: promoting maternal health through community based strategies

    Discontinued Reference number: GID-QS10016

    Quality standard
    Discontinued

  5. Seven day working

    Discontinued Reference number: GID-QS10108

    Quality standard
    Discontinued

  6. Inpatient mental health settings

    Discontinued Reference number: GID-SGWAVE0701

    Safe staffing guideline
    Discontinued

  7. Mental health community settings

    Discontinued Reference number: GID-SGWAVE0702

    Safe staffing guideline
    Discontinued

  8. Management and organisational approaches to safe staffing

    Discontinued Reference number: GID-SGWAVE0761

    Safe staffing guideline
    Discontinued

  9. MRI guided focussed ultrasound for chronic pain

    Discontinued Reference number: GID-IP1043

    Interventional procedures guidance
    Discontinued

  10. Moxetumomab pasudotox for treating hairy-cell leukaemia [ID1142]

    Discontinued Reference number: GID-TA10923

    Technology appraisal guidance
    Discontinued

  11. Dostarlimab with docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6530]

    Discontinued Reference number: GID-TA11655

    Technology appraisal guidance
    Discontinued

  12. Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over [TSID11847]

    In development Reference number: GID-TA11372 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]

    In development Reference number: GID-TA10895 Expected publication date:  29 October 2026

    Technology appraisal guidance
    In development

  14. Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]

    In development Reference number: GID-TA11367 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]

    In development Reference number: GID-TA11117 Expected publication date: TBC

    Technology appraisal guidance
    In development